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Biological mechanisms of gold 
nanoparticle radiosensitization
Soraia Rosa1*, Chris Connolly1,2, Giuseppe Schettino2, Karl T. Butterworth1 and Kevin M. Prise1
Background
Radiation therapy is frequently used in the treatment of cancer, with both curative and 
palliative intent. However, radiation doses that can be delivered to patients are limited 
by toxicity in the surrounding healthy tissue. Many efforts in Radiation Oncology have 
focussed on approaches that aim to preferentially sensitize tumours to radiation whilst 
minimizing effects in normal tissues. An approach to maximize the differential response 
between tumour and normal tissue response, termed therapeutic ratio, is through the 
introduction of high-atomic number (Z) material into the target. Gold (Z  =  79) is a 
promising radiosensitizer in this regard due to its high atomic number and mass energy 
coefficient relative to soft tissue. As shown in Fig. 1, the mass energy coefficient of gold is 
100–150 times greater than that of soft tissue in the keV energy range (Hubbell and Selt-
zer 1996). Consequently, there is an increased probability of photoelectric interaction at 
lower energy levels, resulting in increased energy deposition at the target site. However, 
considering the depth dose limitations of keV X-rays, MV energies are used as the clini-
cal standard for external beam radiotherapy. At these energies, significant radiosensiti-
zation would not be expected based on the ratio of mass energy absorption coefficients 
of gold and soft tissue.
Abstract 
There has been growing interest in the use of nanomaterials for a range of biomedi-
cal applications over the last number of years. In particular, gold nanoparticles (GNPs) 
possess a number of unique properties that make them ideal candidates as radio-
sensitizers on the basis of their strong photoelectric absorption coefficient and ease 
of synthesis. However, despite promising preclinical evidence in vitro supported by 
a limited amount of in vivo experiments, along with advances in mechanistic under-
standing, GNPs have not yet translated into the clinic. This may be due to disparity 
between predicted levels of radiosensitization based on physical action, observed 
biological response and an incomplete mechanistic understanding, alongside current 
experimental limitations. This paper provides a review of the current state of the field, 
highlighting the potential underlying biological mechanisms in GNP radiosensitization 
and examining the barriers to clinical translation.
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Despite this, observed experimental findings deviate from predicted levels of radiosen-
sitization, with effects observed at concentrations lower than predicted. Figure 2 shows 
the X-ray dose modification results against the predicted degree of dose enhancement, 
based on the gold concentrations and X-ray energies used for a range of experimental 
studies (Butterworth et al. 2012). The observed degree of radiosensitization in almost all 
of the experimental results is much greater than the predicted increase in physical dose. 
Physical dose variation between differing nanoparticle preparations and cell lines can be 
seen to be much smaller than predicted, highlighting this as an unknown in cellular radi-
obiological response which is not driven by increasing the total dose delivered to the cells 
behind the radiosensitizing properties of gold nanoparticles (Butterworth et al. 2013).
Fig. 1 Photon mass energy absorption coefficients of soft tissue and gold. The ratio of the mass energy 
absorption coefficients is shown as a function of photon energy (Hubbell and Seltzer 1996)
Fig. 2 Comparison of predicted and observed values of dose enhancement for gold nanoparticles at both 
megavoltage and kilovoltage energies. “Increase in physical dose” here refers to the ratio of the additional 
dose deposited by X-rays in the system due to the addition of GNPs to that which would be deposited in 
the absence of gold. The observed data in this figure are dose modification results from in vitro experiments, 
while the predicted dose increase is based on the gold concentrations and X-ray energies used. The dashed 
line shows the trend which would be followed if the sensitizer enhancement ratio directly followed predicted 
increases in physical dose (Butterworth et al. 2013)
Page 3 of 25Rosa et al. Cancer Nano  (2017) 8:2 
The ISO international standard defines nanoparticles as ‘particles which typically do 
not exceed 100  nm in any of their dimensions’ (Michael et  al. 2005). GNPs consist of 
a gold core which can be generated from various synthesis techniques to give rise to a 
wide range of different sizes and shapes, covered by a surface coating (Grzelczak et al. 
2008). The surface coating can be functionalized for several uses, such as imaging, deliv-
ery and diagnostics (Rana et al. 2012; Ghosh et al. 2008; Mieszawska et al. 2013; Sperling 
et al. 2008).
This review follows on from our 2012 paper “Physical basis and biological mecha-
nisms of gold nanoparticle radiosensitization” and aims to review the current state of 
the field. This will be accomplished by addressing three main points: the physical basis of 
GNP radiosensitization; the biological mechanisms of GNP radiosensitization; and the 
uptake, imaging potential and toxicity of GNPs in biological systems.
Physical basis of GNP radiosensitization
It is known that ionizing radiation can directly or indirectly damage DNA and disrupt 
the atomic structure of other biomolecules (Kavanagh et al. 2013; Azzam et al. 2012). 
DNA repair mechanisms may fail leading cells to stop dividing, die or be mis-repaired, 
thus acquiring mutations that can result in malignant transformation (Begg et al. 2011). 
Therefore, avoiding normal tissue is of significant importance in reducing secondary 
side effects of radiotherapy.
However, one of the major challenges of radiotherapy is its lack of selectivity due to 
the similar mass energy absorption properties of both cancer and healthy tissues (But-
terworth et al. 2012). In order to overcome this, agents such as metal-based nanopar-
ticles (with high Z) have been found to improve the contrast between tumour and soft 
tissues, thus presenting radiosensitizing properties and potentially improving tumour 
control, reducing side effects and increasing survival when compared to radiotherapy 
alone (Herold et al. 2000; Regulla et al. 2002). Those absorb more energy per unit mass 
than soft tissue increasing the local dose deposited in the tumour (Hubbell and Seltzer 
1996).
The main physical mechanisms through which radiation interacts with nanoparticles 
in the keV range are the Compton and Photoelectric effects, where an incident photon 
can either be partially or fully absorbed by an electron from the atom, causing its ejec-
tion (McMahon et al. 2016). The Photoelectric effect is a competing process in which 
the electrons are ejected preferentially from an inner atomic orbital. The vacancy left 
can then be filled by another outer shell electron that falls to its place, further releasing 
low-energy photons promoting a cascade release of secondary electrons (Butterworth 
et al. 2012). This process is called the Auger cascade and it is the major contribution to 
the production of low-energy electrons that have a range of few micrometres and cause 
highly localized ionizing events (Fig. 3) (Butterworth et al. 2012; Xie et al. 2015).
High-Z elements such as iodine, gadolinium and gold have been shown to have the 
ability to image and radiosensitize tumours (Herold et  al. 2000; Regulla et  al. 2002; 
Luchette et al. 2014; Martin 2002). Furthermore, gold has been shown to be biocompat-
ible which makes it an ideal candidate as a radiosensitizer (Shukla et al. 2005; Hainfeld 
et al. 2010; Hainfeld et al. 2004).
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GNPs were initially thought to enhance radiosensitization through physical processes 
but extensive data have shown chemical and biological components involved in the 
radiosensitization process as there is a poor correlation between experimental biological 
results and dosimetric calculations (Butterworth et al. 2012; Ionita et al. 2005; Jain et al. 
2011).
Simulations suggest that the presence of 1% of gold could double the dose deposited 
using X-rays at keV energies and experimental evidence has demonstrated their ability to 
radiosensitize (Cho 2005). On the other hand, theoretical calculations predict that using 
MV X-ray sources there would be no significant increase in the dose deposited (But-
terworth et al. 2012, 2013). Recently, it has been demonstrated by Monte Carlo simula-
tions that there is an increase in secondary electron production when gold is irradiated 
with X-rays at 6 MV compared to water (Ka 2015). Also, in vitro and in vivo experimen-
tal evidence demonstrates a higher radiosensitization effect compared to the predicted 
increase in physical dose expected, in this energy range, suggesting a strong biological 
component in the radiosensitization process as shown in Fig. 2.
Biological mechanisms of GNP radiosensitization
The main mechanisms identified as being involved in the biological response of cells 
to gold nanoparticle radiosensitization are the production of ROS and oxidative stress, 
DNA damage induction, cell cycle effects and potential interference with the bystander 
effects (Fig. 4) as described in the following sections in more detail.
ROS and oxidative stress
Gold is believed to be chemically inert. However, growing evidence suggests that their 
surface is electronically active, thus catalysing chemical reactions and promoting an 
increase in the production of ROS (Ionita et al. 2005; Mikami et al. 2012; Ionita et al. 
Fig. 3 Schematic illustration of the photoelectric, Compton and Auger Effects. The Compton effect is repre-
sented in blue, the photoelectric effect in green and the Auger effect in red as described above
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2007; Zhang et  al. 2003). This seems to be more evident in small NPs (nanoparticles) 
<5 nm in diameter that present a greater surface area-to-volume ratio (Li 2006; Hvolbæk 
et al. 2007; Cheng et al. 2012). One of the identified mechanisms as a possible reason for 
cytotoxicity is through the interaction of the NP surface with O2. In this process, donor 
electrons are transferred from the surface of the NPs to oxygen molecules generating 
superoxide, which can lead to ROS production through dismutation. This has been iden-
tified for single-component materials and for transition metals on the nanoparticle sur-
face, such as Fe and vanadium, which take part in the formation of active sites (Li 2006).
In addition to reactive radicals on the NP surface, there are other sources of oxida-
tive stress such as the redox groups in the coating, contaminants from the production 
method of non-metal NPs and oxidant-inducing properties of NPs (Li 2006; Fard et al. 
2015; Tournebize et al. 2012). Oxidative stress causes damage to cell membranes, DNA 
and protein being identified so far as one of the major causes of NP cytotoxicity (Pan 
et  al. 2009; Xia et  al. 2006). Several reports of ROS production and oxidative stress 
induced by nanoparticles alone have been published as well as in combination with ion-
izing radiation as discussed below.
Nanoparticle‑induced oxidative stress
In vitro reports have shown enhanced ROS production in the presence of GNPs and 
the absence of radiation by various groups (Li 2006; Pan et al. 2009; Coulter et al. 2012; 
Wahab et al. 2014; Chompoosor et al. 2010; Tang et al. 2015; Mateo et al. 2014). Mito-
chondria seem to play a role in it with data indicating loss of function due to high 
intracellular ROS levels. ROS can oxidize the mitochondrial membrane disrupting its 
potential and leaking more superoxide anions into the cytosol which can in turn be con-
verted into H2O2 molecules. These further diffuse across membranes and damage DNA 
(Hei 2015; Havaki et al. 2015).
This is supported by experimental findings using 1.4-nm triphenyl monosulfonate 
(TPPMS)-coated GNPs that promote loss of mitochondrial potential through elevated 
Fig. 4 Schematic representation of the biological mechanisms involved in GNP radiosensitization. GNPs 
influence oxidative stress, DNA damage, cell cycle and bystander effects
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oxidative stress causing necrotic cell death (Pan et al. 2009). Moreover, it was also found 
that antioxidants containing thiol groups bind to the surface of GNPs. This suggests that 
GNPs can bind these antioxidants inside cells inhibiting endogenous reducing agents 
from acting and therefore reduce the redox capacity of the cells (Pan et al. 2009). GNPs 
with different sizes, shapes and surface properties can also promote apoptosis or necro-
sis through ROS generation (Coulter et al. 2012; Wahab et al. 2014; Chompoosor et al. 
2010; Tang et  al. 2015; Mateo et  al. 2014). Tiopronin-coated GNPs led to necrosis by 
enhanced ROS production after 24-h exposure in HeLa and L929 (fibroblast) cells (Li 
2006). Also, dose dependency has been found to increase ROS production with cit-
rate GNPs. These lead to apoptosis due to mitochondrial dysfunction with associated 
upregulation of caspase 3 and 7 (Wahab et al. 2014). Furthermore, mitochondrial mem-
brane polarization is decreased and mitochondrial oxidation is increased when cells are 
exposed to GNPs (AuroVistTM) (Taggart et al. 2014). Moreover, in an indirect way, Au 
(gold) clusters (Au25peptide9) have been shown to dramatically increase ROS produc-
tion via inhibition of thioredoxin reductase 1 (TrxR1) activity (Liu et al. 2014). TrxR1 is a 
regulator of redox reactions within cells and its binding to the GNP surface dramatically 
increased ROS levels inducing apoptosis (Arnér and Holmgren 2000; Fang et al. 2005; 
Tonissen and Trapani 2009; Omata et al. 2006).
In combination with ionizing radiation, GNPs contribute to an increased radiosensi-
tization through which enhanced radical production has been observed following irra-
diation in the presence of glucose-capped GNPs with 90 kVp and 6 MV X-rays (Geng 
et al. 2011). Also, GNPs in water exposed to 100 kVp X-rays can promote an increase 
in hydroxyl radicals (1.46 fold) and superoxide anions (7.68-fold) (Misawa and Taka-
hashi 2011). These increased levels of ROS and oxidative stress can trigger apoptosis as 
observed with 14-nm particles, in ovarian cancer cells, exposed to a MV and kV X-ray 
source (Geng et al. 2011).
Taggart et al. (2016) established a biological mechanism significantly contributing to 
radiosensitization, using 1.9-nm thiol-coated GNPs. Irradiation in the presence of GNPs 
led to an interaction between GNPs and the cell membrane protein disulfide isomer-
ase (PDI), resulting in the disruption of thiol balance within the cell, thus causing cel-
lular redox imbalance and ultimately oxidative stress. This leads to significant increases 
in cell killing, causing the GNPs to act as radiosensitizers. Variation in the expression 
levels of PDI in cancerous cells provides some insight into the range of radiosensitization 
observed across cell types.
In the next section, we highlight situations where radiosensitization enhancement has 
been achieved resorting to nanoparticles.
Nanoparticle‑enhanced radiosensitization
Gold nanoparticle-mediated enhanced radiosensitization has been achieved by several 
research groups.
It was found using 50-nm GNPs that radiosensitized HeLa cells when irradiated 
with 220 kVp X-rays giving a DEF (dose enhancement factor) of 1.43 greater than that 
observed for smaller nanoparticles (from 14 to 74  nm). The cellular uptake rate was 
higher for the 50-nm GNPs, which was correlated with an increased radiosensitiza-
tion, compared to the smaller GNPs tested, and concentration dependent (Chithrani 
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et al. 2010). Also, functionalized Glu (thioglucose)-GNPs and AET (cysteamine)-GNPs 
exposed to 200 kVp X-rays and gamma rays demonstrated a significant increase in cell 
death in breast cancer cells compared to naked GNPs (Kong et al. 2008). Further experi-
ments demonstrated that 1.9-nm GNPs (AuroVistTM) following 2 Gy radiation exposure 
(225 kVp) radiosensitize cells increasing apoptotic levels (Taggart et al. 2014). Moreover, 
in vitro studies have demonstrated GNPs’ ability to radiosensitize tumours at clinically 
relevant energies. At highest energies (6 MV), this has been shown by Chithrani et al. 
(2010). This is supported by 1.9-nm GNPs (AuroVistTM) that radiosensitize at 6 MV, 
and 15 MV X-rays with DEFs of 1.29 and 1.16 in MDA-MB-231 cells (Jain et al. 2011).
Hainfeld demonstrated evidence of radiosensitization in mammary tumour-bearing 
mice using 1.9-nm GNPs and 250 kVp X-ray radiation. Mice irradiated together with 
GNPs had 86% 1-year survival contrasting with 20% for X-rays alone (Hainfeld et  al. 
2004). Furthermore, citrate-coated GNPs that had a low radiosensitization effect in vitro 
with a DEF of 1.08 promoted a delay in tumour growth in B16F10 murine melanoma 
model. This was accompanied with increased survival from 20 days for non-irradiated 
mice to 55  days for mice irradiated with 6 MV and 65  days for mice irradiated with 
GNPs (Chang et al. 2008).
Although radiosensitization can be observed in some cell lines, others like DU145 
human prostate cancer cells that uptake GNPs do not show significant effects at kV 
nor at MV energies (sensitization enhancement ratio: 0.97–1.08) (Jain et  al. 2011). A 
summary of radiosensitizing experiments combining GNPs and ionizing radiation is 
presented in Table 1. Cumulatively, these data strongly suggest a significant biological 
component in GNP radiosensitization; however, the exact cellular mechanisms remain 
to be fully elucidated.
Cell cycle effects
GNPs may enhance radiosensitization by causing cell cycle disruption and inducing 
apoptosis. The sensitivity and consequent biological effects of radiation exposure are 
dependent on the cell cycle phase. Different cell cycle phases present differential radia-
tion sensitivity with late S-phase cell being the most radioresistant and late G2 and mito-
sis being the most sensitive (Pawlik and Keyomarsi 2004). In response to radiation, cells 
activate cell cycle checkpoints in G1, S and G2 phases in order to repair genomic defects, 
maintaining its integrity, or prevent cell division by activating cell death mechanisms 
(Kastan and Bartek 2004). Materials other than gold, such as tachpyridine, have been 
shown to induce cell cycle arrest in G2/M phase most likely due to its metal binding 
activity (Turner et al. 2005). However, GNPs have been more extensively studied leading 
to several other reports of cell cycle distribution alterations (Geng et al. 2011; Roa et al. 
2009; Kang et al. 2010; Mackey et al. 2013; Mackey and El-Sayed 2014; Ganesh Kumar 
et al. 2015).
So far, very few studies have been reported to analyse the effects of GNPs in the 
cell cycle after radiation exposure. Roa et al. (2009) found that GNPs (Glucose-GNPs, 
10.8  nm) alone can promote an increase in the G2/M phase in DU-145 cancer cells. 
When irradiated using a Cs-137 source, G0/G1 phase has been shown to accelerate and 
arrest DU-145 cells in the G2/M phase. In these cells, increased expression of cyclin 
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Table 1 Summary of radiosensitizing experimental data obtained with ionizing radiation 
and gold nanoparticles
Author Size (nm) Concentration Surface coating Cell model Source energy DEF/effect
In vitro
 Bobyk et al. 
(2013)
1.9
15
10 mg/ml, 15 min Thiol F98 glioma cells 50 keV, 6 Gy Sensitization 
ratio of 1.92 for 
1.9 nm particles 
and 1.4 for 
15 nm particles
 Butterworth 
et al. (2010)
1.9 10, 100 µg/ml Thiol AGO-1552B
Astro
DU-145
L132
MCF-7
MDA-MB-231
PC-3
T98G
160 kVp 1.97
0.96
0.81
0.87
1.09
1.11
1.02
1.91
 Chang et al. 
(2008)
13 10 nM Citrate B16F10 6 MV e− Significant 
decrease in SF 
@ 8 Gy
 Chattopadhyay 
et al. (2013)
30 2.4 mg/ml PEG, HER2 
targeted
MDA-MB-231 100 kVp 1.6 (targeted)
1.3 (untargeted)
 Chen et al. 
(2015)
28 36 µg/ml BSA U87 160 kVp 1.37
 Chithrani et al. 
(2010)
14
50
74
7 × 109 NPs/ml Citrate HeLa 105 kVp
220 kVp
660 keV
6 MV
1.66
1.43
1.18
1.17
 Coulter et al. 
(2012)
1.9 12 µM
(500 µg/ml)
Thiol MDA-MB-231
DU-145
L132
160 kVp 1.8
 Cui et al. (2014) 2.7 0.5 mg/ml Tiopronin MDA-MB-231 225 kVp 1.04–1.44
 Geng et al. 
(2011)
14 1.25, 2.5, 5 nM Glucose SK-OV-3 90 kVp
6 MV
1.44
1.3–1.37
 Jain et al. (2014) 1.9 12 µM
(500 µg/ml)
Thiol MDA-MB-231 160 kVp 1.41
 Jain et al. (2011) 1.9 12 µM
(500 µg/mL)
Thiol MDA-MB-231
L132
DU-145
160 kVp.
6 MV
15 MV
1.41
1.29
1.16
 Joh et al. (2013) 12 1 mM PEG U251 150 kVp 1.3
 Kaur et al. (2013) 5–9 5.5 µmol/mL Glucose HeLa Gamma (60-Co)
Carbon (62 MeV)
1.52
1.39
 Khoshgard et al. 
(2014)
47–52 50 µM PEG, Folate-
conjugated
HeLa Gamma (60-Co) 1.64 (targeted)
1.35 (untargeted)
 Kong et al. 
(2008)
10.8 15 µM Cysteamine/
glucose
MCF-7 200 kVp
662 keV
60-Co
1.3 (cysteamine)
1.6 (glucose)
 Liu et al. (2010) 6.1 0.4–1 mM PEG EMT-6
CT26
6.5 keV
8.048 keV
160 kVp
6 MV
3 MeV proton
2–45% decrease in 
survival rate
 Liu et al. (2008) 4.7 500 µM PEG CT26 6 MV 1.33–1.59
 Liu et al. (2015) 14.8 1.5–15 µg/ml Citrate HeLa 50 kVp
X-rays
70 keV/µm 
carbon
1.14–2.88
1.27–1.44
 Ngwa et al. 
(2013)
50 0.2 mg/ml Methyl polymer HeLa I-125 seeds with 
average pho-
ton energy of 
28 keV
1.7–2.3
 Rahman et al. 
(2009)
1.9 0.25, 0.5, 1 mM Thiol BAEC 80 Kvp
150 kVp,
6 MV
12 MV
20
1.4
2.9
3.7
 Roa et al. (2009) 10.8 15 nM Glucose DU-145 662 keV (137-Cs) 1.24–1.38
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Table 1 continued
Author Size (nm) Concentration Surface coating Cell model Source energy DEF/effect
 Taggart et al. 
(2014)
1.9 12 µM (500 µg/
ml)
Thiol MDA-MB-231
T98G
DU-145
225 kVp 1.17–1.23
1.35–1.9
1.01–1.1
 Wang et al. 
(2013)
13 20 nM Glucose A549 6 MV 1.49
 Wang et al. 
(2015)
16
49
20 nM Glucose MDA-MB-231 6 MV 1.49 (16 nm)
1.86 (49 nm)
 Wolfe et al. 
(2015)
31 × 9 0.3 OD PEG, goserelin-
conjugated 
nanorods
PC-3 6 MV 1.36 (targeted)
1.19 (non targeted)
 Zhang et al. 
(2008)
30 15 nM Glucose DU-145 200 kVp >1.3
 Zhang et al. 
(2012)
4.8
12.1
27.3
46.6
0.05 mM PEG HeLa 662 keV (137-Cs) 1.41 (4.8 nm)
1.65 (12.1 nm)
1.58 (27.3 nm)
1.42 (46.6 nm)
 Zhang et al. 
(2014)
<2 50 µg/ml GSH or BSA HeLa 662 keV (137-Cs) 1.3 (GSH)
1.21 (BSA)
In vivo
 Chang et al. 
(2008)
13 200 µl, 200 nM 
GNPs IV
Citrate B16F10 6 MeV e− Tumour growth 
delay
 Chattopadhyay 
et al. (2013)
30 0.8 mg Au
i.t.
PEG, HER2 
Targeted
MDA-MB-361 100 kVp, 11 Gy Tumour growth 
inhibition
 Chen et al. 
(2015)
28 1.3 mg/mL
i.v.
BSA U87 160 kVp, 3 Gy 
@ 2 h post 
injection, 2 Gy 
@ 24 h post 
injection
Tumour regression
 Hainfeld et al. 
(2004)
1.9 1.35 g Au/kg,
2.7 g Au/kg
i.v.
Thiol EMT-6 250 kVp,
26 Gy
50% and 86% 
long-term 
survival at 1.35 g 
and 2.7 g Au/kg
 Hainfeld et al. 
(2010)
1.9 1.9 g/kg
i.v.
Thiol SCCVII 68 keV,
42 Gy,
157 keV,
50.6 Gy
Increase median 
survival (53 vs 
76 days and 
31 vs 49 days 
at 68 keV and 
157 keV)
 Hainfeld et al. 
(2013)
1.9 4 g Au/kg
i.v.
Thiol Tu-2449 100 kVp, 30 Gy 50% long-term 
tumour free 
survival
 Joh et al. (2013) 12 1.25 g Au/kg
i.v.
PEG U251 175 kVp, 20 Gy Increased median 
survival (28 vs 
14 days)
 Miladi et al. 
(2014)
6.6 50 µl, 50 mM
i.t.
DTDTPA, 
DTDTPA-Gd
U87 Mean energy of 
90 keV
DTDTPA increased 
lifespan up to 
117.9%
DTDTPA-Gd 
increased 
lifespan up to 
473.3%
 Wolfe et al. 
(2015)
31 x 9 100 µl, 40 µM 
GNPs
i.v.
PEG PC3 6 MV Tumour growth 
delay
 Zhang et al. 
(2012)
4.8
12.1
27.3
46.6
4 mg/kg
i.v.
PEG HeLa 662 keV Tumour growth 
inhibition
 Zhang et al. 
(2014)
<2 10 mg/kg
i.p.
GSH or BSA U14 662 keV 55% (GSH) and 
38% (BSA) 
decrease in 
tumour volume
Comparison between GNPs’ radiosensitizing effect obtained with different energy sources, cell models and NP 
characteristics
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kinases (cyclin B1 and E) involved in the regulation of the cell cycle was found together 
with a decreased expression of p53 (tumour protein 53) and cyclin A.
However, most studies have been performed in the absence of radiation and showed 
distinct results (Wahab et al. 2014; Arnér and Holmgren 2000; Taggart et al. 2016; Kang 
et al. 2010; Mackey et al. 2013; Mackey and El-Sayed 2014; Ganesh Kumar et al. 2015; 
Cui et al. 2014). Thioglucose-coated 14-nm gold nanoparticles promoted an increase in 
the G2/M cell phase, compared to the control, which lead to enhanced SK-OV-3 cell sen-
sitivity to 6 MV X-ray exposure (Geng et al. 2011). The effects of nuclear-targeted GNPs 
have also been investigated. The results indicated that nanoparticles alone increase in the 
sub-G1 population and disruption of the G1/S transition inducing apoptosis in cancer 
cells (Kang et al. 2010; Mackey et al. 2013). Another study involving 30-nm NLS (nuclear 
localization sequence)-GNPs in human oral squamous carcinoma (HSC-3) has shown 
an increase in S phase and a decrease in G2/M phase sub-population. In combination 
with 5′-fluorouracil that is active during the S phase, these cells were chemosensitized 
(Mackey and El-Sayed 2014). Furthermore, bacteria-mediated anti-proliferative GNPs 
demonstrated G2/M arrest accompanied with the inhibition of tubulin polymerization 
and increased activation of caspases 8, 9 and 3, in DU145 cells, suggesting increased 
apoptosis levels (Ganesh Kumar et al. 2015). Despite the results demonstrating GNPs’ 
influence in the cell cycle, there are other reports indicating no significant interference 
(Pan et al. 2009; Cui et al. 2014; Butterworth et al. 2010). This has been reported with 
2.7-nm tiopronin-GNPs and 1.4-nm triphenyl monosulfonate-GNPs (Pan et  al. 2009; 
Cui et al. 2014). However, the results might be cell line dependent as found using 1.9-
nm GNPs (AuroVistTM) and two different cell lines, DU-145 and MDA-MB-231 cells. 
An increase in the sub-G1 population of DU-145 cells was seen after 48-h incubation, 
whereas this was not detected in MDA-MB-231 cells (Butterworth et al. 2010). Again, 
the coating and size of the nanoparticles induce distinct responses in the various cell 
lines. The variety of concentrations, coatings, materials and cell lines makes it very hard 
to draw any conclusions regarding the exact mechanism of action of NPs. However, the 
alterations induced by GNPs in cell kinetics could be associated to the accumulation 
in G2/M which is known to be the most radiosensitive, thus increasing GNP-mediated 
radiosensitization.
DNA damage and repair
Another mechanism involved in GNP-induced radiosensitization is DNA damage and 
repair. Radiation itself induces double-strand breaks (DSBs) in DNA and their repair is 
essential for cell survival. Given the importance of DNA stability in determining cellular 
propagation, it is a key target for agents that attempt to halt cancer cells from divid-
ing. Thus, cytotoxic targeting DNA agents such as cisplatin, gemcitabine and mitomycin 
C have been tested regarding their ability to act as radiosensitizers (Choudhury et  al. 
2006). The induction of DSBs has also been reported in the presence of GNP γ-H2AX 
foci analysis (Chithrani et  al. 2010; Banáth and Olive 2003). Early DNA damage (1  h 
post irradiation) caused by GNPs appears to be related to its presence in the perinu-
clear region at the time of irradiation. However, late DNA damage (24 h post irradiation) 
seems to be related to other indirect processes such as radical production after interac-
tion with water (Mcquaid et al. 2016).
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Studies conducted with 50-nm citrate GNPs demonstrated increased foci number 
after being irradiated with 220  kVp and 6 MV energies for 4 or 24  h. The increased 
residual damage suggests possible inhibition or delay in DNA damage induction and/
or repair which can be essential to the radiosensitization mechanism of NPs (Chithrani 
et al. 2010).
This has been further confirmed with 2.7-nm tiopronin-GNPs irradiated with 250 kVp 
X-rays. An increased residual DNA damage after being irradiated for 24 h was found in 
the samples where NPs were present. Contrastingly, no significant effect was observed 
only at 30 min post irradiation suggesting that the GNPs had no influence on the induc-
tion of DNA damage (Cui et al. 2014). Furthermore, GNPs have been found to induce 
DSBs in hepatocellular carcinoma cells after radiation exposure. Residual damage has 
also been found when the cells were irradiated in the presence of nanogold indicating 
influence in the repair mechanisms of the cells (Zheng et al. 2013). GNPs might not have 
all the same mechanisms of action and may induce distinct repair kinetics across differ-
ent cell lines. For instance, BSA (bovine serum albumin)-capped GNPs induce increased 
γ-H2AX foci after 2 or 4 h of irradiation but no change is observed in the samples incu-
bated for 24 h. This implies that these NPs do not influence cellular repair mechanisms 
(Chen et al. 2015). Other NPs such as 1.9-nm (AuroVistTM) have been reported to have 
no impact on the formation or repair in DSBs, neither at 1 h nor at 24 h after irradiation, 
in MDA-MB-231 cells (Jain et al. 2011).
Even if NPs demonstrate a radiosensitizing potential by promoting dose enhancement 
and potentially contributing to increased DNA DSB formation, the lack of consistency of 
cell lines, radiation sources and energies, treatment conditions and nanoparticles prop-
erties lead to incomparable results, making it difficult to draw a conclusion. The under-
standing of how different properties of the GNPs, irradiation conditions and biological 
response of various cell lines contribute to DNA damage and repair could further shed 
light on the underlying mechanism of GNP influence on DNA damage response.
Potential impacts of bystander effects of GNP radiosensitization
In addition to direct radiation effects, communication between cells is also very impor-
tant after radiation exposure. Cells that have not been directly exposed to radiation can 
receive signals from irradiated ones that were in the vicinity responding in a similar way 
to direct exposure (Najafi et al. 2014). This process is called the bystander effect and it 
can occur in different cell types such as endothelial cells, fibroblasts, lymphocytes and 
tumour cells (Havaki et al. 2015; Prise and O’Sullivan 2009; Butterworth et al. 2013). The 
bystander signals involved in this process may cause altered gene expression, damage in 
the DNA and chromosomes, cell proliferation alterations, cell death or changes in the 
translation process in non-irradiated cells (Najafi et al. 2014).
The main bystander signalling molecules are reactive oxygen species or nitrogen reac-
tive species (RNS), cytokines, miRNA (micro-ribonucleic acid) or extracellular oxi-
dized DNA (ecDNA) (Azzam et  al. 2002, 2004; Barber 2011). These are released into 
the surrounding environment and reach the bystander cells through passive diffusion 
or by binding to receptors on their plasma membrane (Barber 2011; Azzam et al. 2003). 
Also it can occur by direct cell-to-cell contact via gap junction intercellular communica-
tion (GJIC) (Azzam et al. 2001). Furthermore, exosomes carrying miRNA are believed 
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to mediate intercellular signalling between tumour cells and bystander cells (Melo et al. 
2016; Yang et al. 2011; Umezu et al. 2013; Sánchez et al. 2015). 21 miRNAs have been 
found recently to be up- or downregulated after ionizing radiation exposure. Extracel-
lular miR-1246 (micro-ribonucleic acid 1246) in particular appears to be increasing with 
irradiation dose. It was found to enhance proliferation and resistance in lung cancer cells 
by targeting death receptor 5 (DR5) although through a non-exosome associated path-
way (Yuan et al. 2014). Nevertheless, soluble miRNAs involved in bystander signalling 
can be generated due to ROS, RNS, cytochrome c and cytokines (Hei 2015; Shao et al. 
2011; He et al. 2011).
As NPs have been shown to alter cytokine and gene expression as well as ROS produc-
tion, their single presence in the tumour environment could further change the way cells 
respond to radiation. NPs could also mediate bystander signalling, for example, small 
titanium dioxide NPs induce higher levels of oxidative stress and production of inflam-
matory cytokines. The expression of cytokine macrophage inflammatory protein-1 alpha 
(MIP-1α) and high-mobility group protein 1 (HMGB1) were found to be expressed in 
the presence of these NPs, both in vitro and in vivo (Fujiwara et al. 2015). This may play 
a role in enhancing oxidative stress as HMGB1 is known to be an inflammatory mac-
rophage-secreted cytokine, which is activated by TNFα (tumour necrosis factor alpha) 
and IL-1β (interleukin 1 beta) (Andersson et al. 2000; Tang et al. 2009). The latter will in 
turn promote the secretion of HMGB1 (Tang et al. 2009). This creates a cycle that can 
propagate inflammation and it might also propagate bystander effects as cytokines like 
TNFα and IL-1β have been shown to be elevated in bystander cells (Zhou et al. 2008). 
The increased production of IL (interleukin) and TNFα stimulates nitrogen oxide (NO) 
and ROS biosynthesis by activating NF-kB (nuclear factor kappa B) transcription fac-
tor, directly or indirectly, which in turn leads to the activation of iNOS (inducible nitric 
oxide synthase) and COX-2 (cyclooxygenase-2) genes’ expression (Zhou et  al. 2008). 
iNOS controls the production of NO and COX-2 is involved in ROS production, there-
fore increasing oxidative stress (Najafi et al. 2014; Hei et al. 2011). Moreover, small air-
way epithelial cells (SAECs) exposed to GNPs are able to induce protein expression in 
neighbouring lung fibroblasts in co-culture systems. This study found that 47 proteins 
were upregulated, while 62 were downregulated in the fibroblasts receiving signals 
from the incubated SAECs with GNPs. Most of the proteins identified are involved in 
cell adhesion, extracellular matrix and cytoskeleton remodelling. Plasminogen activa-
tor, PLAU (plasminogen activator urokinase), UPA (urokinase-type plasminogen acti-
vator) and GRO-1 (growth-regulated oncogene 1) that are implicated in cell migration 
were found to be downregulated, potentially decreasing it. Contrastingly, proteins that 
promote cell adhesion such as Paxillin (PXN), breast cancer anti-oestrogen resistance 1 
(BCAR1) and Caveolin-1 (Cav-1) were upregulated (Ng et al. 2015).
PXN, a focal adhesion (FA), is an associated adapter protein that regulates cell spread-
ing and motility. BCAR1 has been correlated with controlling the spread and motility 
of cancer cells through regulating FA (Machiyama et al. 2014; Miao et al. 2012; Schaller 
2001). Furthermore, Cav-1 is known to mediate cancer metastasis (Brennan et al. 2012). 
Also Cav-1 can promote NF-kB activation and lung inflammatory response, through 
eNOS (endothelial nitric oxide synthase) and NO production (Mirza et al. 2010). These 
results might indicate airway inflammation since it can be related to increased adhesion 
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molecules (Garrean et al. 2006; Liu et al. 2014). The elevated cell adhesion was accom-
panied by altered F-actin stress fibre arrangement in the cytoskeleton of the lung fibro-
blasts. Similarly, there was an increase in vinculin binding sites that are associated with 
F-actin anchoring to the cell membranes of the fibroblasts, which can potentially lead 
to enhanced vascular permeability as previously described (Snyder-Talkington et  al. 
2013; Pacurari et al. 2012; Setyawati et al. 2013). Overall, cytoskeleton remodelling and 
increased cell adhesion may affect lung function, thus reminding of the importance of 
understanding the cellular communication pathways in the presence of NPs even in the 
absence of radiation (Ng et al. 2015).
In addition to cellular bystander responses at the tissue and whole organism levels, a 
phenomenon called an abscopal effect can occur. There is a response of an organ/site 
distant from the irradiated one, where the cells are not close to each other, which has 
been observed in patients undergoing localized radiotherapy (Kaminski et  al. 2005). 
The importance of the abscopal effect remains to be fully understood. It might have the 
potential to either increase cell killing or protect normal tissues (Prise and O’Sullivan 
2009). The role of NPs in mediating abscopal effects has not been elucidated due to a 
lack of in vivo and clinical studies.
As nanoparticles may induce changes in cell signalling, leading to various responses 
depending on their size, shape and coating, understanding which signalling pathways 
are influenced could potentially help understand their mechanism of action in the 
bystander/abscopal and radiosensitization effects.
Uptake, imaging potential and toxicity of GNPs in biological systems
Uptake
Radiation absorption and dose deposition is thought to be partially reliant on the num-
ber of gold nanoparticles present within the cell, meaning that cellular uptake and distri-
bution of GNPs will have a direct influence on the degree of radiosensitization observed 
(Chithrani and Chan 2007). This makes cellular uptake of GNPs an important metric 
in modifying sensitivity to radiotherapy. Modelling carried out to replicate GNP uptake 
equal to 1% mass in the cytosol demonstrated dose enhancement in both the nucleus 
and mitochondria, despite cytosol localization. It was concluded that the physical mech-
anism of dose enhancement was caused by photoelectron delocalization from the cyto-
sol to cell organelles, meaning that the dose enhancement effects were not limited to the 
vicinity of the nanoparticles (McNamara et al. 2016).
Both uptake potential and blood circulation times have been shown to be closely asso-
ciated with nanoparticle size. The optimal size for uptake has been found to be between 
25 and 50  nm, with particles smaller than 10  nm or larger than 100  nm exhibiting a 
reduced uptake potential (Yang et al. 2014).
Chithrani et al. found the uptake of gold nanoparticles to be heavily reliant on their 
size and shape. Internalization of smaller particles is observed to be a more rapid process 
than that of larger particles. This is important as the uptake of nanoparticles into the cell 
will have a direct influence on the level of radiosensitization (Chithrani and Chan 2007). 
Coulter et  al. reported the maximum amount of nanoparticle uptake to occur within 
the first few hours of exposure of cells to 1.9-nm GNPs, with a plateau being reached 
after 6  h. However, they also highlighted the difficulty in making direct comparisons 
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with previous work as a result of the number of variables involved, as uptake may differ 
depending on the nanoparticle shape, size, coating, concentration and charge, as well 
as cell type (Coulter et al. 2012). These studies show cellular uptake to be dependent on 
concentration, time and cell type. Experiments carried out in hypoxic cell models saw 
reduced GNP uptake, thought to be linked to reduced energy production in the cells 
(Jain et al. 2014).
While GNPs will passively accumulate in tumours due to the EPR effect, their encap-
sulation within liposomes has been shown to result in higher cellular internalization 
(Maeda et  al. 2003). Uncapped nanoparticles bind to various plasma proteins upon 
administration, resulting in a large number being internalized by macrophages and 
removed from circulation. Liposomes have a history of being used for drug encapsu-
lation and delivery as their large size (100–200  nm) ensures that they can pack many 
GNPs within their lipid bilayers. Small nanoparticles encapsulated within liposomes 
show better passive accumulation within the tumour than non-encapsulated nanoparti-
cles (Chithrani et al. 2010). The contents can then be released through a triggering tech-
nique, allowing the nanoparticles to penetrate the tumour tissue more effectively (Kneidl 
et  al. 2014). Alternatively, nanoparticles capped with PEG (polyethylene glycol) alone 
will show an increase in their half-life in blood (Hirn et  al. 2011), while HSA (human 
serum albumin)-conjugated gold nanoparticles have shown increased retention in the 
lungs and brain compared with both apoE (apolipoprotein E)-capped and citrate-stabi-
lized nanoparticles (Schuffler et al. 2014).
In contrast to passive targeting, active targeting is the functionalization of the GNP 
surface with peptides, ligands or antibodies in order to preferentially target tumour 
cells (Schuemann et al. 2016), taking advantage of the overexpressed surface receptors 
of cancer cells. Not only does this increase the therapeutic ratio through achieving a 
greater nanoparticle concentration within the tumour, but also reduces the overall vol-
ume of gold required for treatment. Sykes et al. (2014) carried out an investigation into 
the impact that nanoparticle size has on active and passive targeting. Gold nanoparti-
cles with diameters of 15, 30, 60 and 100 nm were prepared with the surface modified 
with either PEG or PEG conjugated to transferrin. Those nanoparticles modified with 
transferrin showed a significant increase in tumour accumulation in vivo, with accumu-
lation in the 60-nm particles being 1.9 times greater than that in their passive counter-
parts. However, it is of note that while the PEG-only nanoparticles were slower, they also 
diffused deeper into the tumour. Popovtzer et al. (2016) successfully demonstrated sig-
nificant improvement in tumour radiosensitivity using GNPs covalently conjugated to 
CTX monoclonal antibody in mice. This actively targeted the tumour with no evidence 
of early or delayed toxicity, confirmed by histological characterization of the tumour and 
adjacent tissue both 1 and 6 weeks post treatment. TNF has been covalently conjugated 
to gold nanoparticles, with the aim of the interaction between TNF and its receptor 
TNF-R1 causing active targeting of the tumour cells. Molecules of PEG-Thiol are inter-
spersed between TNF molecules, and nanoparticles may be treated with a coating to 
increase cellular internalization.
Tumour blood vessels may also be promising targets, as sub-100-nm-diameter nano-
particles are expected to accumulate in the vasculature (Perrault et al. 2009). The impor-
tant role of endothelial cells within the tumour vasculature makes them ideal targets 
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with high potential clinical impact. However, a model generated by Berbeco et al. exam-
ining gold nanoparticles as tumour vascular disrupting agents found the boosted irra-
diation of endothelial cells alone was not viable due to the short range of the ionizing 
particles. The combination of tumour-targeting functionalization with image-guided 
radiotherapy could combat this by ensuring that the tumour has maximum levels of 
GNPs present during irradiation. Nanoparticle-mediated drug delivery to the tumour 
vasculature has been shown to have anti-metastatic effects and tumour gold content will 
give a good indication of overall tumour vascularity (Murphy et al. 2008). Shifting nan-
oparticle accumulation from the reticuloendothelial system (RES) to other organs will 
result in longer retention times, though unanticipated retention over prolonged periods 
of time may result in cytotoxic effects (Balasubramanian et al. 2010). This accumulation 
of GNPs may be achieved through the addition of peptides, allowing more site-specific 
delivery. For example, insulin has been used to improve the delivery of gold nanoparti-
cles to target sites in the brain (Shilo et al. 2014), while other peptide-capped gold nano-
particles have been shown to pass through the blood–brain barrier using a number of 
mechanisms (Velasco-Aguirre et al. 2015). The ability to accurately target organ sites for 
uptake greatly enhances the radiosensitizing potential of GNPs.
In conclusion, while there are several benefits to passive targeting, it is noticeably less 
efficient in slow-growing models when compared to fast-growing models, since the for-
mer have more mature and intact blood vessels (Kunjachan et  al. 2015). Cellular tar-
geting can face problems in the way of tissue barriers which vascular targeting avoids 
by providing nanoparticles with direct access or binding to the overexpressed targets. 
Attacking the vasculature can also have the added benefit of affecting the numerous 
cancer cells that rely on it for growth (Kunjachan et  al. 2014, 2015). GNP uptake has 
been shown to be reliant on several variables, including nanoparticle shape, size, charge 
and concentration, alongside the cell type. While the EPR effect results in the passive 
accumulation of GNPs within the tumour, encapsulation and specific coatings allow for 
increased cellular targeting and retention.
Imaging
A consequence of the increasing use of gold nanoparticles in biomedical applications is 
the need for their accurate and efficient detection in both biological and tumour sam-
ples. The ability to determine nanoparticle location provides insights of uptake pathways 
as well as potentially identifying nanoparticle location as a cause of cytotoxicity. Accu-
rate imaging of nanoparticle location within a sample will help achieve precise dose dep-
osition and may also provide understanding of mechanisms behind radiosensitization. 
To quantify the uptake and distribution of nanoparticles within cells, several imaging 
techniques can be used. The physical properties of gold nanoparticles also allow them to 
be used as imaging agents. Miladi et al. (2014) used 2.4-nm GNPs coated with DTDTPA 
(dithiolated diethylenetriamine pentaacetic acid)-gadolinium chelates to combine MRI 
(magnetic resonance imaging) and radiosensitizing effects. The DTDTPA coating acts 
in preventing the clumping of GNPs along with slowing their uptake by the RES. Osteo-
sarcoma- and gliosarcoma-bearing rats were injected with the nanoparticles, which were 
then monitored using MRI. The rats were then irradiated at the point when the highest 
content of nanoparticles was observed in the tumour. Several approaches can be used 
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to image the uptake and distribution of GNPs throughout the cell, including localized 
surface plasmon resonance, photoacoustic imaging, computerized tomography, X-ray 
fluorescence computed tomography and electron microscopy. Each technique will have 
individual advantages and limitations, so it can be worthwhile to apply multiple tech-
niques in order to improve the reliability of diagnostics and treatments (Botchway et al. 
2015).
A characteristic affecting the imaging techniques that can be used with gold nanopar-
ticles is localized surface plasmon resonance (LSPR). This is instigated by their ability to 
absorb and scatter specific wavelengths of light and refers to the resonance established 
between incident light photons and particle surface electrons. The LSPR of a nanoparti-
cle can provide information about its overall size and structure, as when these change, 
so does its resonant frequency. While LSPR has a high sensitivity and relatively low 
cost, it can be time consuming to set up depending on the target (Petryayeva and Krull 
2011). Photoacoustic imaging (PA) involves irradiating tissue using a nonionizing short-
pulsed laser beam. Exogenous contrast agents absorb this energy to produce ultrasound 
waves, which are received using a transducer. The mechanical acoustic waves are then 
converted into an electronic signal which is processed to form an image. As the photoa-
coustic waves are only generated within the tissue sample, there is reduced background 
interference. PA gives higher spatial resolution and deeper imaging depth compared to 
fluorescence optical imaging, while the lack of ionizing radiation also makes it a safer 
option than computerized tomography (CT) (Wang 2008; Pan et al. 2013; Li and Chen 
2015).
The strong effect demonstrated by gold nanoparticles allows them to be used as con-
trast agents in photoacoustic imaging. Changing the shape and size of the nanoparticles 
that are being used enables the tuning of the magnitude of light being absorbed and scat-
tered and when compared with other contrast agents, such as imaging dyes and silver 
nanoparticles, they demonstrate a greater absorbance (Menon et  al. 2013; Huang and 
El-Sayed 2010).
The accumulation of gold nanoparticles in tumours due to the EPR makes them well 
suited for photoacoustic imaging. This helps determine the location of the tumour along 
with assessing the vasculature and accumulation of therapeutic agents. However, the 
photostability of gold nanoparticles is a potential limitation as they can change shape 
due to high laser energies. Zhang et  al. utilized GNPs as PA agents to detect human 
breast cancer xenografts in mice. The nanoparticles were found to accumulate within 
the tumours after 5 h following injection via tail vein and a significant enhancement in 
signal intensity was seen. This accumulation and signal enhancement would allow gold 
nanoparticles to be used as both tumour contrast agents and mediators of cancer ther-
apy (Chang et al. 1999; Zhang et al. 2009).
The high atomic number and potentially long circulation time make gold nanoparti-
cles ideal contrast agents for CT (Cormode et al. 2014). Hainfeld et al. used 1.9-nm gold 
nanoparticles as a contrast agent for X-ray therapy in rats. Contrast was estimated to be 
~3 times greater than that of iodine at 100 keV, a useful range for clinical CT. The agent 
was then observed to be excreted via the kidneys with no observed toxicity. Further 
work used gold nanoparticles as a contrast agent to detect smaller tumours (1.5 mm). 
Nanoparticles were observed to accumulate in the tumours, and micro-CT allowed for 
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quantification of this. They also noted that there was a greater uptake of nanoparticles 
without any attached antibody, which they believed to be due to the smaller size.
Alric et al. used a gadolinium chelate to produce a nanoparticle that could be used for 
both MRI and CT imaging. The nanoparticles were found to circulate freely in blood 
with no adverse accumulation in the lungs, liver and spleen (Alric et al. 2008).
X-ray fluorescence computed tomography (XFCT) is an imaging technique that aims 
to simultaneously determine the identity, quantity and spatial distribution of elements 
within imaged objects. Previously, Cheong et al. had been successful in accurately iden-
tifying the location of a GNP-filled object within a small animal-sized plastic phantom, 
as well as quantifying the amount of GNPs present. However, at the time their technique 
was not yet practical for routine in vivo use (Cheong et al. 2010). More recently, Mano-
har et  al. (2016) demonstrated the use of benchtop XFCT for imaging a small animal 
that had been injected with gold nanoparticles. However, they found that their set-up 
required further refinement before it could be used routinely.
Electron microscopy is well suited to imaging gold nanoparticles due to their high 
electron density. It allows for the determination of the size and shape down to 1 nm and 
as a result is commonly used when characterizing nanoparticles. However, transmission 
electron microscopy (TEM) has a complicated and time-consuming sample preparation, 
and individual nanoparticles are not also distinguishable if their size is below the resolu-
tion limit (Schrand et al. 2010). Scanning electron microscopy (SEM) requires coating 
samples in a conductive metal, usually composed of nanometer-sized clusters. The simi-
larities between samples prepared using conventional methods and metal nanoparticles 
make SEM incompatible. However, Goldstein et al. (2014) developed a simplified proce-
dure that involved chromium coating, allowing them to observe cellular uptake of GNPs.
The physical properties of GNPs allow them to be used with a wide range of imaging 
techniques. This not only allows for the quantification of their uptake and distribution, 
but also makes them potential contrast agents. The advantages and limitations of each 
technique indicate that it may be necessary for more than one technique to be applied to 
improve reliability.
Toxicity
GNPs must exhibit safe behaviour after cellular uptake to be considered potential 
radiosensitizers. If individual nanoparticles are found to be cytotoxic or to reduce cell 
viability, then they might not be suitable for clinical use. Following IV (intravenous) 
injection, both the biodistribution and clearance of nanoparticles are influenced by vari-
ous physiological factors (bloodstream, opsonization, endothelial permeability of vessels 
and organs) as well as the individual physicochemical properties of nanoparticles (size, 
charge and surface chemistry). These physicochemical properties can be altered to con-
trol their biodistribution. It is preferable that particles are later removed through urine 
as this implies that there has been no degradation.
There is a level of uncertainty regarding the cytotoxicity of GNPs. While bulk gold 
is known to be biologically safe, functionalized GNPs have shown obvious cytotoxicity 
(Goodman et  al. 2004). Size, concentration, cell type and treatment time are all basic 
parameters to be considered when examining the cytotoxicity of GNPs. Size is an 
Page 18 of 25Rosa et al. Cancer Nano  (2017) 8:2 
important factor, as very small particles have been found to be highly toxic, and larger 
particles are relatively nontoxic (Pan et al. 2007).
Zhang et  al. summarized that while high gold concentrations cause an obvious 
decrease in cell viability, low gold concentrations do not appear to influence viability. 
Nanoparticles with a diameter of 15  nm were found to be nontoxic up to 75  µg/ml, 
though cell viability was obviously affected at concentrations of gold >150  µg/ml. At 
600 µg/ml, cell viability was reduced to 41.8%, compared to 93.9% at 18.75 µg/ml (Zhang 
et al. 2009).
A study by Connor et al. found no difference in growth rates between untreated cells 
and cells exposed to 25 mM concentration of 18-nm nanoparticles over the course of 
5 days. The uptake and localization of the nanoparticles in the cell were confirmed by 
TEM, leading to the conclusion that nanoparticles are not inherently toxic to human 
cells. However, it was noted that the determination of whether the nanoparticles are 
modified by their environment is important, as this may result in significant variation to 
their clinical applications (Connor et al. 2005).
In 2004, Hainfeld et  al. (2004) carried out work that involved injecting mice with 
2.7 g Au/kg per body mass. These mice survived over a year without showing any obvi-
ous clinical effects, suggesting that in this case the nanoparticles were biocompatible. 
Further work by Hainfeld et al. (2013) showed that irradiation with 11.2-nm nanopar-
ticles increased long-term survival (over 1 year) of mice by 50%, while none of the mice 
receiving the same treatment without nanoparticles survived longer than 150 days. As 
the LD50 (lethal dose at 50%) of these nanoparticles was >5 g Au/kg, a dose of 4 g Au/
kg was used, showing that by using the appropriate dose of nanoparticles, toxicity can be 
averted and lifespan can be greatly improved.
The effects of 5- and 15-nm GNPs on mouse fibroblast cells were examined by Corade-
ghini et al. to provide data on the toxic potential of different sized nanoparticles. Using 
a colony forming efficiency (CFE) assay, the in vitro toxicity of gold nanoparticles was 
tested at the concentrations of 10–300 µM and at the times of 2, 24 and 72 h. Significant 
cytotoxicity was only seen in cells treated with 5-nm nanoparticles at a concentration 
over 50 µM and an exposure time of 72 h, with no significant cytotoxicity observed in 
the 15-nm nanoparticles. TEM imaging showed that cellular internalization occurred 
for both sizes of nanoparticles (Coradeghini et al. 2013).
Stefan et al. examined the effects of 12- and 22-nm chitosan-capped gold nanoparti-
cles on rats treated with lipopolysaccharide (LPS). Brain and liver tissue reactivity was 
assessed following 8 days of administration. They found that while the body weight of 
the treated rats did not change significantly, the ratio between liver and body weights 
significantly increased with both nanoparticle sizes, especially the 22-nm ones, sug-
gesting potential liver toxicity. The 22-nm nanoparticles also experienced a significant 
decrease in their brain-to-body weight ratio, suggesting possible brain damage. Dark-
field imaging showed the agglomeration of nanoparticles within cytoplasmic cellular 
regions as a potential cause of this damage. This was not seen when using the 12-nm 
nanoparticles (Stefan et al. 2013).
While it remains a challenge to accurately estimate the cellular response to a given 
nanoparticle size, there are general trends which can be trusted. While both the cell type 
and surface properties of the nanoparticle play a role in nanoparticle uptake, smaller 
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nanoparticles are more likely to be passively internalized, though are also more likely to 
have a cytotoxic effect (Shang et al. 2014).
As there is increasing interest in using nanomaterials in both research and a clinical 
setting it is important that nanoparticle cytotoxicity can be tested in a fast and efficient 
manner. Karlsson et al. used the in vivo assay “ToxTracker” with a panel of metal oxide 
and silver based nanoparticles. This comprises of a panel of mouse embryonic stem cells, 
each containing a GFP (green fluorescent protein)-tagged reporter for a distinct cellular 
signalling pathway. In this way it is possible to identify DNA damage caused by direct 
DNA interaction, oxidative stress and general cellular stress (Karlsson et al. 2014). If this 
assay was adapted for GNPs it may elucidate their cytotoxic properties.
Conclusion
Despite NPs’ potential to induce radiosensitization in cancer cells, there are several chal-
lenges towards clinical translation which has, to date, led to only a few clinical trials 
being undertaken with the majority being liposome based and related to targeting, not 
involving radiosensitization (Anselmo and Mitragotri 2016). Among these challenges, 
there are some inconsistencies found in the mechanisms of action of different GNPs, 
reduced long term side effects in vivo studies and the limited demonstration of thera-
peutic efficacy at megavoltage energies, at which radiotherapy is clinically performed 
(McMahon et al. 2016).
Regardless of the distinct simulation results using megavoltage energies, an experi-
mentally significant increase in DNA damage in the presence of GNPs has been 
observed. At 6 MV, the number of DSBs increases in HeLa cells, with increasing depth 
and as a function of the field size (Berbeco et al. 2012). Also, at MV energies it is possible 
to achieve dose enhancement in vivo (Chang et al. 2008; Mousavie Anijdan et al. 2013). 
Furthermore, a number of studies conducted at MV energies are also required prior to 
clinical application to support the results obtained at keV energies that most experi-
ments are performed at. Also the dose delivered needs to be adjusted as NPs increase 
the dose deposition tremendously in its vicinity and in a clinical context it is usually 
much lower to limit exposure of organs at risk (McMahon et al. 2011). Moreover, NPs 
may change cellular communication influencing the clinical outcome, therefore requir-
ing further studies in this field.
Nevertheless, using NPs can be an asset not just to radiosensitize cells but also to pro-
vide contrast as they can be imaged. This would provide a theranostic agent, combin-
ing therapeutic and imaging potential in one NP, thus improving accuracy and results of 
treatment delivery. Despite its potential applications, without understanding the mech-
anisms mediating the biological effects in cells, it is difficult to move towards clinical 
applications in a robust way.
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